10-Q: TNF Pharmaceuticals Reports Q1 2025 Results Amidst Going Concern Uncertainty and Nasdaq Compliance Concerns
Sentiment:
Quarterly Report
TNF Pharmaceuticals reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern, while also facing potential delisting from Nasdaq.
Capital raiseThe company's ability to continue as a going concern is dependent on obtaining additional capital financing.The company expects to seek additional funding through private equity or debt financings.The issuance of additional equity would result in dilution to existing stockholders.
Worse than expectedThe company reported a net loss and negative cash flow from operations.Management expresses substantial doubt about the company's ability to continue as a going concern.The company received a Nasdaq notification regarding non-compliance with the minimum bid price rule.
Summary
- TNF Pharmaceuticals, Inc. reported its financial results for the first quarter of 2025.
- The company sustained a net loss attributable to common stockholders of $1,938,239 and negative cash flows from operations of $2,640,240 for the three months ended March 31, 2025.
- As of March 31, 2025, TNF Pharmaceuticals had cash of $73,244 and marketable securities of $5,805,331.
- The company's working capital was $1,840,793, and stockholders' equity was $8,690,909, including an accumulated deficit of $131,076,525.
- TNF Pharmaceuticals is focused on developing Isomyosamine and Supera-CBD.
- The company received a letter from Nasdaq indicating non-compliance with the minimum bid price requirement, providing a compliance period until September 15, 2025.
- Management expresses substantial doubt about the company's ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued, dependent upon its ability to obtain additional capital financing.
- The company is involved in ongoing legal proceedings, including actions by Raymond Akers.
Sentiment
Score: 3
Explanation: The document presents a concerning financial situation with a net loss, going concern uncertainty, and Nasdaq compliance issues. While there are some positive aspects, the overall tone is negative from an investment perspective.
Positives
- The company is actively pursuing the development of Isomyosamine and Supera-CBD, with ongoing clinical trials and research programs.
- TNF Pharmaceuticals has taken steps to address the Nasdaq compliance issue, indicating a proactive approach to maintaining its listing.
- The company has secured amendments to its Series F and Series F-1 agreements, providing some flexibility in managing its financial obligations.
- The company has a registration statement on Form S-3 covering certain securities, which was declared effective by the SEC on August 12, 2024.
Negatives
- The company reported a net loss attributable to common stockholders of $1,938,239 for Q1 2025.
- TNF Pharmaceuticals has negative cash flows from operations of $2,640,240 for Q1 2025.
- The company's cash position is low, with only $73,244 in cash as of March 31, 2025.
- Management expresses substantial doubt about the company's ability to continue as a going concern.
- TNF Pharmaceuticals received a Nasdaq notification regarding non-compliance with the minimum bid price rule.
- The company is involved in ongoing legal proceedings, including actions by Raymond Akers.
Risks
- The company's ability to continue as a going concern is dependent on obtaining additional capital financing, which may not be available on acceptable terms or at all.
- Failure to regain compliance with Nasdaq's minimum bid price requirement could result in delisting, negatively impacting the company's stock price and investor confidence.
- The ongoing legal proceedings could result in significant expenses and divert management's attention from the company's core business.
- The company's reliance on preferred stock and warrant issuances for financing could lead to further dilution of existing stockholders' equity.
- The full ratchet anti-dilution provisions in the Series F, F-1 and G agreements could result in significant dilution to existing shareholders.
- The company's ability to develop and commercialize its product candidates is subject to regulatory approvals and market acceptance, which are uncertain.
Future Outlook
The company's future is dependent on its ability to obtain additional capital financing and successfully develop and commercialize its product candidates.
Industry Context
The company operates in the highly competitive pharmaceutical industry, facing challenges related to drug development, regulatory approvals, and market acceptance.
Comparison to Industry Standards
- It is difficult to compare TNF Pharmaceuticals directly to industry standards due to its unique focus on Isomyosamine and Supera-CBD.
- However, the company's financial performance can be compared to other small-cap pharmaceutical companies in similar stages of development.
- Many small-cap pharmaceutical companies have similar cash positions and accumulated deficits.
- The company's research and development expenses are in line with other companies in the industry.
- The company's ability to secure additional financing and achieve regulatory approvals will be critical to its long-term success.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Bylaw Amendment | The board of directors of the Company approved the first amendment (the First Amendment) to the bylaws of the Company (the Bylaws), effective as of May 9, 2025. The First Amendment amends and restates Article II, Section 2.09 of the Bylaws in its entirety (i) to lower the required stockholder vote in all matters other than the election of directors from the affirmative vote of a majority of the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote on the subject matter to the affirmative vote of a majority of the votes cast by the stockholders present in person or represented by proxy at the meeting and entitled to vote on the subject matter, voting affirmatively or negatively (excluding abstentions and broker non-votes), and (ii) to make a corresponding change to the vote required for class votes. | 2025-05-09 | The change in voting requirements could make it easier for management to pass proposals, as it lowers the threshold for approval. |
Legal Proceedings
- The company is involved in ongoing legal proceedings, including actions by Raymond Akers.
Related Party Transactions
- The company is a party to two Amended and Restated Confirmatory Patent Assignment and Royalty Agreements with SRQ Patent Holdings and SRQ Patent Holdings II, affiliates of Mr. Jonnie Williams, Sr., a former significant stockholder.
- The company is a party to an Amended and Restated Limited License Agreement with MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA).
- The interim Chief Executive Officer, President and Director of PharmaCyte, Joshua Silverman, serves as the Companys Chairman of the Board.
Stakeholder Impact
- Shareholders face potential dilution from future equity issuances and the risk of delisting from Nasdaq.
- Employees face uncertainty due to the company's financial instability and potential for further staff reductions.
- The company's ability to continue its research and development programs is dependent on securing additional funding, which could impact the development of new therapies for patients.
Next Steps
- The company must regain compliance with Nasdaq's minimum bid price rule by September 15, 2025.
- TNF Pharmaceuticals needs to secure additional capital financing to continue its operations.
- The company must continue to advance the development of Isomyosamine and Supera-CBD.
- The company must manage the ongoing legal proceedings.
Key Dates
| Date | Description |
|---|---|
| 2016-12-31 | Date of 2016 Stock Incentive Plan |
| 2017-08-07 | Date the Company adopted the 2017 Stock Incentive Plan |
| 2018-12-07 | Date the Company adopted the 2018 Stock Incentive Plan |
| 2020-08-27 | Date the 2018 Plan was modified to increase the total authorized shares available for future issuance. |
| 2021-04-15 | Date the Company adopted the 2021 Stock Incentive Plan |
| 2023-02-21 | Date the Company entered into a Securities Purchase Agreement (the Series F Purchase Agreement) with certain accredited investors (the Series F Investors) |
| 2024-02-14 | The Company effected a 1-for-30 reverse stock split |
| 2024-05-20 | The Company entered into a Securities Purchase Agreement (the Series F-1 Purchase Agreement) with certain accredited investors (the Series F-1 Investors) |
| 2024-05-20 | The Company entered into a Securities Purchase Agreement (the Series G Purchase Agreement) with certain accredited investors (the Series G Investors) |
| 2024-07-24 | The Companys stockholders approved the adoption of the Certificate of Amendment to the Companys Certificate of Incorporation to increase the number of authorized shares of the Companys Common Stock from 16,666,666 to 250,000,000 |
| 2024-07-25 | The Company filed the Authorized Share Increase Amendment with the Secretary of State of Delaware |
| 2025-03-17 | The Company received a letter from the Listing Qualifications Department of Nasdaq indicating that the Company did not meet the minimum bid price of $ 1.00 per share required for continued listing on The Nasdaq Capital Market |
| 2025-04-08 | The Company entered into an Omnibus Amendment Agreement (April 2025 Amendment Agreement) with the Required Holders |
| 2025-05-13 | Date as of which the registrant had 14,184,088 shares of its Common Stock outstanding. |
| 2025-09-15 | Compliance Period deadline for Nasdaq Listing Rule 5810(c)(3)(A) |
Keywords
Financial Results, Going Concern, Nasdaq Compliance, Isomyosamine, Supera-CBD, Preferred Stock, Warrants, Dilution, TNF Pharmaceuticals, TNFA
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.